Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products-Reference-Cited by-同舟云学术

Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products

Published:2021-02 Issue:2 Volume:24 Page:268-273
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Sirrs Sandra M.,Arthus Marie-Francoise,Bichet Daniel G.,Rockman-Greenberg Cheryl,LeMoine Kaye,Morel Chantal F.,Lachmann Robin,Lynd Larry D.,Wasim Syed,West Michael L.,Hollak Carla

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference29 articles.

1. Evaluating and valuing drugs for rare conditions: no easy answers;Ollendorf;Value Health,2018

2. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?;Rodriguez-Monguio;Orphanet J Rare Dis,2017

3. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL);Annemans;Orphanet J Rare Dis,2017

4. A review of international coverage and pricing strategies for personalized medicine and orphan drugs;Degtiar;Health Policy,2017

5. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost;Rawson;Orphanet J Rare Dis,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Framework for Multistakeholder Patient Registries in the Field of Rare Diseases;Neurology;2024-09-24

2. Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada;Health Policy;2024-05

3. Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public–private partnerships;Journal of Inherited Metabolic Disease;2023-04

4. Access to medicines for rare diseases: A European regulatory roadmap for academia;Frontiers in Pharmacology;2023-02-28

5. Real-world use of orphan medicinal products (OMPs) in rare disease (RD) patients: A population-based registry study;Frontiers in Pharmacology;2022-09-30